SCHEMBL6981317

SCHEMBL6981317

N#CC1Cc2cc3c(cc21)OCO3

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.50
CYP3A4 P08684 2/20 0.50
DRD1 P21728 2/20 0.41
ADRA1A P35348 1/20 0.41
DRD2 P14416 1/20 0.41
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 3/20 0.38
GLA P06280 2/20 0.38
HPGD P15428 2/20 0.38
CASP1 P29466 2/20 0.38
CASP7 P55210 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CYP2D6 P10635 2/20 0.38
ACHE P22303 1/20 0.38
GAA P10253 1/20 0.37
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
HIF1A Q16665 1/20 0.35
CHRNA7 P36544 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9149765 0.75 CYP3A4 (0.42) HTR1ACYP3A4DRD1ADRA1ADRD2
SCHEMBL7540141 0.71 TRPM5 (0.37)
SCHEMBL10292643 0.71 FYN (0.40) DRD1ADRA1ADRD2ALDH1A1KDM4E
SCHEMBL8870189 0.69 HTR1A (0.53) HTR1ACYP3A4DRD1ADRA1ADRD2
SCHEMBL7999291 0.69 HTR1A (0.53) HTR1ACYP3A4DRD1ADRA1ADRD2
SCHEMBL8871523 0.68 HTR1A (0.59) HTR1ACYP3A4DRD1ADRA1ADRD2
Hydrochloric Acid SCHEMBL8871565 0.68 CYP3A4 (0.51) HTR1ACYP3A4DRD1ADRA1ADRD2
SCHEMBL6985110 0.68 MEN1 (0.35)
SCHEMBL9381978 0.67 ALDH1A1 (0.38) CYP3A4DRD1DRD2ALDH1A1CYP2D6
SCHEMBL13428611 0.67 CYP3A4 (0.43) CYP3A4DRD1DRD2ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1146041-B1 Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline SERVIER LAB (FR) 2003-11-12 EP disclosed
US-6420413-B2 1-(6-((DIMETHYLAMINO)METHYL)-1-METHYL-2,3,5,6-TETRAHYDRO-1H -CYCLOBUTA(F) INDOL-6-YL)CYCLOHEXANOL, FOR EXAMPLE; TREATING PSYCHOLOGICAL DISORDERS SUCH AS DEPRESSION, PANIC ATTACKS, PHOBIAS, DRUG ABUSE, AS WELL AS OBESITY AND BULEMIA LES LABORATORIES SERVIER (FR) 2002-07-16 US disclosed
US-20020019380-A1 Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds LES LABORATOIRES SERVIER (FR) 2002-02-14 US disclosed
EP-1146041-A1 Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline ADIR ET COMPAGNIE (FR) 2001-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019380-A1 Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds HSD3B2, HSD3B1, NR1H3 HTR1A 336/4885CYP3A4 307/4885DRD1 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.